# Neoadjuvant Imiquimod Immunotherapy for Oral Cancer

> **NCT04883645** · EARLY_PHASE1 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 16 (actual)

## Conditions studied

- Oral Squamous Cell Carcinoma

## Interventions

- **DRUG:** Imiquimod 5% Cream

## Key facts

- **NCT ID:** NCT04883645
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-07-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04883645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04883645, "Neoadjuvant Imiquimod Immunotherapy for Oral Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04883645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*